Toremifene citrate

QT Prolongation, Avoid CYP3A4 Inhibitors

  • Torimefene has been shown to prolong the QTc interval in a dose- and concentration-related manner.  Prolongation of the QT interval can result in a type of ventricular tachycardia called Torsade de pointes, which may result in syncope, seizure, and/or death.
  • Toremifene should not be prescribed to patients with congenital/acquired QT prolongation, uncorrected hypokalemia or uncorrected hypomagnesemia.
  • Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided

Patient counseling

Package inserts

Updated: January 2018